• Eli Lilly and Co LLY.N reported quarterly adjusted earnings of $3.34​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $2.58. The mean expectation of seventeen analysts for the quarter was for earnings of $3.02 per share. Wall Street expected results to range from $2.68 to $3.73 per share.

• Revenue rose 45.2% to $12.73 billion from a year ago; analysts expected $12.67 billion.

• Eli Lilly and Co's reported EPS for the quarter was $3.06​.

• The company reported quarterly net income of $2.76 billion.

• Eli Lilly and Co shares had risen by 8.8% this quarter and gained 16.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 38.5% in the last three months.​

• In the last 30 days, eleven analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Eli Lilly and Co is $999.06

This summary was machine generated from LSEG data May 1 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)